Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PYX 201

Next Previous
X
Search
Drug Profile

PYX 201

Alternative Names: anti-EDB; PYX-201

Latest Information Update: 28 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Pyxis Oncology
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 20 Nov 2024 Merck and Pyxis oncology enter into clinical trial collaboration agreement to develop PYX 201 in combination with pembrolizumab for Head and neck squamous cell carcinoma, HR+/HER2- breast cancer, Triple-negative breast cancer and sarcoma
  • 20 Nov 2024 Efficacy, adverse events and pharmacokinetic data from a phase I trial in Solid tumours released by Pyxis Oncology
  • 20 Nov 2024 Pyxis oncology plans clinical trial of PYX 201 for head and neck squamous cell carcinoma, HR+/HER2- breast cancer, Triple-negative breast cancer and sarcoma (Combination therapy) in 1Q25

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top